α-Hederin has been found to reverse cisplatin resistance in NSCLC by silencing SLC7A11 and inhibiting miR-96-5p, activating DDIT3/ATF3-mediated ferroptosis [86]. The gene discussed is SLC7A11; the disease is non-small cell lung carcinoma.